新生血管性年龄相关性黄斑变性患者玻璃体内注射抗血管内皮生长因子药物治疗进展  

Progress in treatment of neovascular age-related macular degeneration with intravitreal injection of anti-VEGF drugs

作　　者：罗曼 陈晓隆[1] LUO Man;CHEN Xiaolong(Department of Ophthalmology,Shengjing Hospital of China Medical University,Shenyang 110004,Liaoning Province,China)

机构地区：[1]中国医科大学附属盛京医院眼科,辽宁省沈阳市110004

出　　处：《眼科新进展》2020年第6期582-586,共5页Recent Advances in Ophthalmology

摘　　要：年龄相关性黄斑变性是引起50岁以上人群视力不可逆性损伤的主要原因之一,新生血管性年龄相关性黄斑变性(neovascular age-related macular degeneration,nAMD)也称湿性年龄相关性黄斑变性(wet age-related macular degeneration,wAMD),是其晚期阶段,可导致最严重的视力丧失。血管内皮生长因子(vascular endothelial growth factor,VEGF)是脉络膜新生血管和视网膜渗漏形成的主要因素,抗VEGF治疗是目前唯一实现多数患者视力改善并且停止疾病进展的治疗方法,因此玻璃体内注射抗VEGF药物已经成为wAMD一线治疗方法。用于临床治疗wAMD的抗VEGF药物主要有哌加他尼、贝伐单抗、雷珠单抗、阿柏西普和康柏西普。治疗方案有固定式、按需式以及治疗和延长式治疗方案。Brolucizumab和abicipar pegol是2种新的抗VEGF药物,正处于3期临床试验阶段。本文对以上药物治疗wAMD的研究进展进行综述。Age-related macular degeneration(AMD)is considered one of the main causes of irreversible vision loss in populations over 50 year-old.Wet age-related macular degeneration(wAMD),known as the neovascular age-related macular degeneration(nAMD)is an advanced stage,which is responsible for the most severe vision loss.Vascular endothelial growth factor(VEGF)is the main factor that leads to the development of choroidal neovascularization and retinal leakage.At present,anti-VEGF therapy is the only treatment that achieves vision gains in many patients and halts progression in most of them,and intravitreal injection of anti-VEGF drugs has become the first-line treatment of wAMD.The anti-VEGF drugs used in clinical treatment of wAMD mainly include Pegaptanib,Bevacizumab,Ranibizumab,Aflibercept and Conbercept,and the treatment regimens include fixed,on-demand,and treat-and-extend therapy.Brolucizumab and abicipar pegol,two new anti-VEGF drugs,are undergoing phase 3 clinical trials.The article summaries the research progress of above drugs for the treatment of wAMD.

关 键 词：新生血管性年龄相关性黄斑变性 抗血管内皮生长因子 临床治疗 

分 类 号：R774.1[医药卫生—眼科]